Table 1.

Univariate and multivariate backward stepwise analysis for factors associated with BCSS in the training cohort

Univariate analysisMultivariate analysis
Risk factorsHR (95% CI)PHR (95% CI)P
AgeContinuous1.04 (1.01–1.07)0.004a
Hormonal therapyNo10. 043a1
Yes0.50 (0.25–0.98)0.34 (0.17–0.68)0.002a
Adjuvant chemotherapyNo10.344
Yes1.39 (0.70–2.76)
Presenting tumor size mmContinuous1.01 (1.00–1.02)0.036a
Presenting gradeLow/intermediate10.93
High0.97 (0.80–1.88)
Tumor typeIDC-NST10.608
TypesOther1.20 (0.54–2.84)
ER expressionPositive10.095
Negative1.74 (0.91–3.34)
HER2 statusNormal10.112
Overexpression0.43 (0.15–1.22)
PR expressionPositive10.193
Negative0.59 (0.27–1.30)
Triple-negative phenotypeNo10.205
Yes1.57 (0.78–3.14)
Clinical TNM (c-TNM)Stage II10.002a
Stage III6.39 (1.96–20.83)
Pathologic TNM (yp TNM)Stage 0/I10.003a
Stage II/III5.94 (1.83–19.37)
Number of positive lymph nodesContinuous1.06 (1.03–1.10)0.001a1.07 (1.02–0.11)0.003a
Residual inv CA sizeContinuous1.01 (1.01–1.02)0.0005a
Percentage of tumor size reductionContinuous0.99 (0.98–1.00)0.004a
Percentage of cellularity of residual inv CAContinuous1.03 (1.01–1.04)0.0001a
Percentage of reduction in cellularity of inv≤90%10.0004a
CA (Miller–Payne system)>90%0.54 (0.38–0.76)
Extension and distribution of InvNo cell/scattered10.0004a
Groups or sheets1.81 (1.31–2.50)
FibrosisYes10.00001a
No4.28 (2.22–8.23)5.04 (2.56–9.92)0.000003a
LVIYes10.0003a
No3.26 (1.71–6.21)2.85 (1.47–5.55)0.002a
Ductal carcinomaYes10.144
No1.67 (0.84–3.23)

Abbreviations: IDC-NS, invasive ductal carcinoma-no special type; inv-CA, invasive carcinoma.

  • aStatistically significant P < 0.05.